NASDAQ:ANIP ANI Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ANI Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $27.61 -2.75 (-9.06 %) (As of 09/21/2020 02:35 PM ET) Add Compare Share Today's Range$27.56Now: $27.61▼$29.6250-Day Range$27.62MA: $30.41▼$33.0752-Week Range$25.23Now: $27.61▼$80.87Volume1,648 shsAverage Volume108,700 shsMarket Capitalization$340.02 millionP/E RatioN/ADividend YieldN/ABeta1.3 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingANI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $46.00, ANI Pharmaceuticals has a forecasted upside of 66.6% from its current price of $27.61.Amount of Analyst CoverageANI Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesANI Pharmaceuticals has received 398 “outperform” votes. (Add your “outperform” vote.)Underperform VotesANI Pharmaceuticals has received 385 “underperform” votes. (Add your “underperform” vote.)Community SentimentANI Pharmaceuticals has received 50.83% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ANI Pharmaceuticals and other stocks. Vote “Outperform” if you believe ANIP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ANIP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldANI Pharmaceuticals does not currently pay a dividend.Dividend GrowthANI Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ANI Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $307,800.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 24.80% of the stock of ANI Pharmaceuticals is held by insiders.Percentage Held by Institutions60.33% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ANI Pharmaceuticals are expected to grow by 17.00% in the coming year, from $3.00 to $3.51 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ANI Pharmaceuticals is -16.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ANI Pharmaceuticals is -16.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioANI Pharmaceuticals has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.09 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ANIP Previous SymbolNASDAQ:BPAX CUSIPN/A CIK1023024 Webwww.anipharmaceuticals.com Phone218-634-3500Debt Debt-to-Equity Ratio0.93 Current Ratio1.98 Quick Ratio1.31Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio9.20 P/E GrowthN/A Sales & Book Value Annual Sales$206.55 million Price / Sales1.65 Cash Flow$7.36 per share Price / Cash Flow3.75 Book Value$17.59 per share Price / Book1.57Profitability EPS (Most Recent Fiscal Year)$4.46 Net Income$6.09 million Net Margins-10.27% Return on Equity20.11% Return on Assets8.84%Miscellaneous Employees299 Outstanding Shares12,315,000Market Cap$340.02 million Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $27.61 -2.75 (-9.06 %) (As of 09/21/2020 02:35 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ANIP News and Ratings via Email Sign-up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter. ANI Pharmaceuticals (NASDAQ:ANIP) Frequently Asked Questions How has ANI Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? ANI Pharmaceuticals' stock was trading at $38.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ANIP shares have decreased by 27.9% and is now trading at $27.61. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of ANI Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ANI Pharmaceuticals. When is ANI Pharmaceuticals' next earnings date? ANI Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for ANI Pharmaceuticals. How were ANI Pharmaceuticals' earnings last quarter? ANI Pharmaceuticals Inc (NASDAQ:ANIP) released its earnings results on Thursday, August, 6th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.57 by $0.12. The specialty pharmaceutical company had revenue of $48.47 million for the quarter, compared to the consensus estimate of $45.70 million. ANI Pharmaceuticals had a negative net margin of 10.27% and a positive return on equity of 20.11%. During the same period last year, the company posted $1.44 earnings per share. View ANI Pharmaceuticals' earnings history. What price target have analysts set for ANIP? 3 analysts have issued 12-month target prices for ANI Pharmaceuticals' stock. Their forecasts range from $40.00 to $58.00. On average, they anticipate ANI Pharmaceuticals' share price to reach $46.00 in the next year. This suggests a possible upside of 66.6% from the stock's current price. View analysts' price targets for ANI Pharmaceuticals. Are investors shorting ANI Pharmaceuticals? ANI Pharmaceuticals saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 637,900 shares, an increase of 15.6% from the July 15th total of 552,000 shares. Based on an average daily volume of 134,000 shares, the short-interest ratio is currently 4.8 days. Approximately 6.7% of the shares of the stock are short sold. View ANI Pharmaceuticals' Short Interest. Who are some of ANI Pharmaceuticals' key competitors? Some companies that are related to ANI Pharmaceuticals include Ligand Pharmaceuticals (LGND), Dicerna Pharmaceuticals (DRNA), ZEALAND PHARMA/S (ZEAL), Rocket Pharmaceuticals (RCKT), Heron Therapeutics (HRTX), Arcus Biosciences (RCUS), Generation Bio (GBIO), Intercept Pharmaceuticals (ICPT), ALX Oncology (ALXO), Trillium Therapeutics (TRIL), Amneal Pharmaceuticals (AMRX), Zogenix (ZGNX), Epizyme (EPZM), NGM Biopharmaceuticals (NGM) and Akero Therapeutics (AKRO). View all competitors. What other stocks do shareholders of ANI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (GILD), Micron Technology (MU), Teva Pharmaceutical Industries (TEVA), AbbVie (ABBV), Alibaba Group (BABA), Broadcom (AVGO), Intel (INTC), NVIDIA (NVDA) and Cisco Systems (CSCO). Who are ANI Pharmaceuticals' key executives? ANI Pharmaceuticals' management team includes the following people: Mr. Arthur S. Przybyl, Pres, CEO & Director (Age 62)Mr. Stephen P. Carey, CFO & VP of Fin. (Age 48)Mr. James G. Marken, Sr. VP of Operations & Product Devel. (Age 56)Mr. Robert W. Schrepfer, Sr. VP of Bus. Devel. & Specialty Sales (Age 47) What is ANI Pharmaceuticals' stock symbol? ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP." Who are ANI Pharmaceuticals' major shareholders? ANI Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Federated Hermes Inc. (2.44%), Thompson Siegel & Walmsley LLC (2.42%), Goldman Sachs Group Inc. (2.22%), Assenagon Asset Management S.A. (1.16%), Bank of New York Mellon Corp (0.86%) and Russell Investments Group Ltd. (0.81%). Company insiders that own ANI Pharmaceuticals stock include Arthur Przybyl, David Nash, James G Marken, Meridian Venture Partners Ii L, Patrick D Walsh, Robert W Schrepfer and Thomas Haughey. View institutional ownership trends for ANI Pharmaceuticals. Which institutional investors are selling ANI Pharmaceuticals stock? ANIP stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Nuveen Asset Management LLC, Bank of Montreal Can, Tudor Investment Corp Et Al, Man Group plc, Goldman Sachs Group Inc., Principal Financial Group Inc., and Principal Financial Group Inc.. View insider buying and selling activity for ANI Pharmaceuticals. Which institutional investors are buying ANI Pharmaceuticals stock? ANIP stock was purchased by a variety of institutional investors in the last quarter, including Thompson Siegel & Walmsley LLC, Federated Hermes Inc., Assenagon Asset Management S.A., WINTON GROUP Ltd, Two Sigma Advisers LP, Engineers Gate Manager LP, Aigen Investment Management LP, and UBS Group AG. Company insiders that have bought ANI Pharmaceuticals stock in the last two years include David Nash, Patrick D Walsh, and Thomas Haughey. View insider buying and selling activity for ANI Pharmaceuticals. How do I buy shares of ANI Pharmaceuticals? Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is ANI Pharmaceuticals' stock price today? One share of ANIP stock can currently be purchased for approximately $27.61. How big of a company is ANI Pharmaceuticals? ANI Pharmaceuticals has a market capitalization of $340.02 million and generates $206.55 million in revenue each year. The specialty pharmaceutical company earns $6.09 million in net income (profit) each year or $4.46 on an earnings per share basis. ANI Pharmaceuticals employs 299 workers across the globe. What is ANI Pharmaceuticals' official website? The official website for ANI Pharmaceuticals is www.anipharmaceuticals.com. How can I contact ANI Pharmaceuticals? ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected] This page was last updated on 9/21/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
